Vet Therapeutics Inc develops pet biologics to help treat cancer in companion animals. Vet Therapeutics is developing antibody-based therapies to treat pet cancer and chronic conditions. The Vet Therapeutics team has more than 30 years' experience and a successful track record at developing antibody-based biologics for humans, which is directed towards the development of pet-specific biologics to treat pet cancer and chronic conditions. The company id developing 6 programs for the treatment of B-cell lymphoma, T-cell lymphoma, mast cell tumor, atopic dermatitis, and feline lymphoma, as well as in diagnostics to support lymphoma phenotyping. It has a research license agreement with Crucell Holland B.V to prepare recombinant antibodies. Acquired by Aratana Therapeutics (Nasdaq: PETX) in Ocober 2103, Vet Therapeutics, Inc. now operates as a subsidiary of Aratana Therapeutics, Inc.
